MSX RWA US Stocks Daily Watch: West Pharmaceutical and APLY: Elevated West Valuation and APLY High-Yield Risks, Global Central Bank Hawkishness Triggers Bond Market Turmoil

West Pharmaceutical Services' stock price is $364.98. Organic sales growth is solid, but reported growth will slow due to the SmartDose divestiture and currency headwinds; its valuation is elevated and requires faster EPS growth to justify the price.

No. APLY offers a 30% distribution yield, but there is risk of net asset value (NAV) erosion, and its options liquidity is thin; high distributions may come from return of principal, and total return may be significantly lower than the distribution rate.

Global central banks are responding to the oil price shock with rate hikes, with the European Central Bank (ECB) leading this round of hawkish tightening; the hawkish stance is cooling the global economy.

The French 10-year government bond yield has risen to 4.9%, up 130 basis points over the past six months, indicating that global bond markets are repricing for a more hawkish rate path.

The Fed dot plot implies one more rate hike, while the federal funds futures market is pricing in four rate hikes, creating a clear expectation gap between the two.